Details of Disease

General Information of Disease (ID: DISVONJE)

• Disease Name: Sepsis
• Disease Class: 1G40-1G41: Sepsis
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISVONJE: Sepsis
• ICD Code:
  ICD-11: ICD-11: 1G40-1G41
  ICD-9: ICD-9: 995.91
  Expand ICD-9: 995.91
• Disease Identifiers:
  MONDO ID: MONDO_0006967
  MESH ID: D018805
  MedGen ID: 48626
  HPO ID: HP:0100806

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 6 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cephapirin	DMV2JNY	Approved	Small molecular drug	[1]
Ha-1a	DM3EVLE	Approved	NA	[2]
Nafamostat	DMU1XOD	Approved	Small molecular drug	[3]
Norepinephrine	DMOUC09	Approved	Small molecular drug	[4]
Proflavine	DMF1X5P	Approved	Small molecular drug	[5]
Temocillin disodium	DMD8M5X	Approved	Small molecular drug	[2]

This Disease is Treated as An Indication in 9 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ERITORAN	DMKQZ0L	Phase 3	Small molecular drug	[6]
Resatorvid	DMFMWYC	Phase 3	Small molecular drug	[7]
Tifacogin	DMMO6P0	Phase 3	Small molecular drug	[8]
CaCP-29	DMXFTDF	Phase 2	NA	[9]
DELTIBANT	DM5CB8U	Phase 2	NA	[10]
FE-202158	DM3CVHQ	Phase 2	NA	[11]
YM-264	DMAZNVX	Phase 2	Small molecular drug	[13]
ERB-257	DMKMR2X	Phase 1	NA	[14]
J5dLPS/OMP	DMTLVJG	Phase 1	NA	[15]

This Disease is Treated as An Indication in 1 Drugs in Phase 2 Trial

Drug Name	Drug ID	Highest Status	Drug Type	REF
IC14	DM37CX4	Phase 2 Trial	Monoclonal antibody	[12]

This Disease is Treated as An Indication in 28 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RPAF-AH	DMOVJ60	Discontinued in Phase 3	NA	[16]
Segard	DMIHQZ8	Discontinued in Phase 3	Antibody	[17]
E-5531	DMBFYWU	Discontinued in Phase 2	NA	[18]
GR-270773	DMLD74U	Discontinued in Phase 2	NA	[19]
JTE-607	DM1BQFY	Discontinued in Phase 2	Small molecular drug	[20]
Minopafant	DMVF2R1	Discontinued in Phase 2	Small molecular drug	[21]
MK-287	DMCAKPG	Discontinued in Phase 2	Small molecular drug	[22]
Ro-24-4736	DM01MRZ	Discontinued in Phase 2	Small molecular drug	[23]
SM-10661	DMZYGW0	Discontinued in Phase 2	Small molecular drug	[24]
TCV-309	DM3VZ87	Discontinued in Phase 2	Small molecular drug	[25]
UK-74505	DMAD1S5	Discontinued in Phase 2	Small molecular drug	[26]
ABT-299	DM8GZAS	Discontinued in Phase 1	Small molecular drug	[27]
ALBIFYLLINE	DMVBKLO	Discontinued in Phase 1	Small molecular drug	[28]
CS-4771	DMVDLT4	Discontinued in Phase 1	NA	[29]
CY-1788	DMCKNBD	Discontinued in Phase 1	NA	[30]
DACOPAFANT	DMDUZ5W	Discontinued in Phase 1	Small molecular drug	[31]
ONO-1714	DML7Q56	Discontinued in Phase 1	Small molecular drug	[32]
SB 249417	DM2C0LN	Discontinued in Phase 1	Antibody	[33]
Benafentrine dimaleate	DMXH3A2	Terminated	Small molecular drug	[34]
Bepafant	DMVK78Q	Terminated	Small molecular drug	[35]
CL-184005	DMJBGI1	Terminated	Small molecular drug	[36]
GINKOLIDE B	DMLIM7B	Terminated	Small molecular drug	[37]
NCY-118	DMSQXYQ	Terminated	NA	[38]
QRS-5-005	DMTDZ25	Terminated	NA	[39]
RAS-111	DMO53O5	Terminated	NA	[40]
Ro-24-0238	DMJQA0D	Terminated	Small molecular drug	[41]
Tenecrin	DMAQMNQ	Terminated	NA	[42]
TIAPAFANT	DM0SCDB	Terminated	Small molecular drug	[43]

This Disease is Treated as An Indication in 15 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABTAA	DM79DSN	Investigative	Antibody	[44]
AXImab	DM3QWYP	Investigative	Monoclonal antibody	[45]
CN-16	DMEDX5D	Investigative	NA	[45]
DD7	DMV0JQG	Investigative	Aptamer	[46]
ED1	DM5QS17	Investigative	Aptamer	[46]
ED45	DMX32JY	Investigative	Aptamer	[46]
GCH-01	DMLW1AV	Investigative	NA	[45]
HBN-3	DMDF9T5	Investigative	NA	[45]
HM 401	DMFWQQJ	Investigative	NA	[45]
L-97-1 intravenous	DMYDR2N	Investigative	Small molecular drug	[47]
MFH-147	DM4OP6L	Investigative	NA	[45]
Recombinant soluble CD6	DM615UZ	Investigative	NA	[45]
Recombinant soluble human CD5	DMRCB02	Investigative	NA	[45]
Sepcidin	DMA59OB	Investigative	NA	[45]
VGV-S	DMJ9ZWI	Investigative	NA	[45]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 062720.
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006437)
• [4] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 505).
• [5] Drug information of Proflavine, 2008. eduDrugs.
• [6] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4919).
• [7] ClinicalTrials.gov (NCT00633477) Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure. U.S. National Institutes of Health.
• [8] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. JAMA. 2003 Jul 9;290(2):238-47.
• [9] ClinicalTrials.gov (NCT02246595) Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction. U.S. National Institutes of Health.
• [10] CP-0127, a novel potent bradykinin antagonist, increases survival in rat and rabbit models of endotoxin shock. Agents Actions Suppl. 1992;38 ( Pt 3):413-20.
• [11] ClinicalTrials.gov (NCT01612676) Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock. U.S. National Institutes of Health.
• [12] ClinicalTrials.gov (NCT00233207) IC14 Antibodies to Treat Individuals With Acute Lung Injury. U.S. National Institutes of Health.
• [13] Current Pharmaceutical Design. Page(175).
• [14] ClinicalTrials.gov (NCT00722202) Study Evaluating the Safety and Pharmacokinetics (PK) of Ascending Single IV Doses of ERB-257 in Healthy Japanese Males. U.S. National Institutes of Health.
• [15] Phase I study of detoxified Escherichia coli J5 lipopolysaccharide (J5dLPS)/group B meningococcal outer membrane protein (OMP) complex vaccine in human subjects. Vaccine. 2003 Nov 7;21(31):4576-87.
• [16] ClinicalTrials.gov (NCT00037687) Safety and Efficacy of Recombinant Human Platelet-Activating Factor Acetylhydrolase for the Treatment of Severe Sepsis. U.S. National Institutes of Health.
• [17] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002771)
• [18] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003108)
• [19] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010119)
• [20] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014630)
• [21] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002131)
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001713)
• [23] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001180)
• [24] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004382)
• [25] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002130)
• [26] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001719)
• [27] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1849).
• [28] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003224)
• [29] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032166)
• [30] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003725)
• [31] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000051)
• [32] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013758)
• [33] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800010912)
• [34] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000110)
• [35] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6078).
• [36] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001674)
• [37] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1862).
• [38] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005128)
• [39] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009237)
• [40] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030078)
• [41] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003729)
• [42] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003195)
• [43] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6080).
• [44] Amelioration of sepsis by TIE2 activation-induced vascular protection. Sci Transl Med. 2016 Apr 20;8(335):335ra55.
• [45] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [46] Therapeutic applications of aptamers. Expert Opin Investig Drugs. 2008 Jan;17(1):43-60.
• [47] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 389).